Title : Rucaparib in ovarian cancer: an update on safety, efficacy and place in therapy.

Pub. Date : 2018

PMID : 29977351






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Phase II and III trials have documented that rucaparib has single-agent antitumor activity in patients with high-grade ovarian carcinoma, with both BRCA-mutated (germline and somatic) and with homologous recombination deficiency (HRD). rucaparib BRCA1 DNA repair associated Homo sapiens